Climb Bio Inc
CLYM5.440USD
+0.790+16.99%
終値 02/06, 16:00（ET）15分遅れの株価
370.92M時価総額
損失額直近12ヶ月PER
詳細情報 Climb Bio Inc 企業名
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The Company is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Climb Bio Incの企業情報
企業コードCLYM
会社名Climb Bio Inc
上場日Aug 10, 2021
最高経営責任者「CEO」Brennan (Aoife M)
従業員数17
証券種類Ordinary Share
決算期末Aug 10
本社所在地20 William Street
都市WELLESLEY HILLS
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02481
電話番号18668572596
ウェブサイトhttps://climbbio.com/
企業コードCLYM
上場日Aug 10, 2021
最高経営責任者「CEO」Brennan (Aoife M)
Climb Bio Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
+48132.00%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
Dr. Douglas E. (Doug) Williams, Ph.D.
Dr. Douglas E. (Doug) Williams, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Cindy Driscoll
Ms. Cindy Driscoll
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Dr. Susan Altschuller, Ph.D.
Dr. Susan Altschuller, Ph.D.
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.13K
+48132.00%
Dr. Andrew David Levin, M.D., Ph.D.
Dr. Andrew David Levin, M.D., Ph.D.
Director
Director
--
--
Dr. Judith A. Dunn, Ph.D.
Dr. Judith A. Dunn, Ph.D.
Independent Director
Independent Director
--
--
Dr. Stephen Thomas, Ph.D.
Dr. Stephen Thomas, Ph.D.
Director
Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Alexander (Bo) Cumbo
Mr. Alexander (Bo) Cumbo
Independent Director
Independent Director
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
RA Capital Management, LP
16.57%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.97%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
他の
70.41%
株主統計
株主統計
比率
RA Capital Management, LP
16.57%
Pontifax Venture Capital
7.64%
The Vanguard Group, Inc.
1.97%
Affinity Asset Advisors LLC
1.91%
Kynam Capital Management LP
1.51%
他の
70.41%
種類
株主統計
比率
Venture Capital
24.25%
Hedge Fund
9.63%
Investment Advisor
7.53%
Investment Advisor/Hedge Fund
1.15%
Individual Investor
0.81%
Research Firm
0.80%
他の
55.83%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
180
50.12M
94.21%
+7.08K
2025Q3
182
50.11M
95.00%
-5.30M
2025Q2
174
55.41M
95.70%
-2.05M
2025Q1
161
57.46M
90.60%
-8.97M
2024Q4
149
56.10M
86.82%
+979.54K
2024Q3
120
56.83M
81.50%
+4.66M
2024Q2
84
51.93M
31.41%
+31.40M
2024Q1
82
18.86M
80.37%
-3.42M
2023Q4
86
18.86M
80.98%
+125.11K
2023Q3
87
18.73M
82.50%
-1.84K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
RA Capital Management, LP
17.90M
26.26%
-13.52M
-43.02%
Dec 12, 2025
Pontifax Venture Capital
5.21M
7.64%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
1.32M
1.93%
-15.44K
-1.16%
Sep 30, 2025
Affinity Asset Advisors LLC
1.30M
1.91%
-200.00K
-13.33%
Sep 30, 2025
Kynam Capital Management LP
1.03M
1.51%
--
--
Sep 30, 2025
Tang Capital Management, LLC
1.00M
1.47%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
694.98K
1.02%
-134.65K
-16.23%
Sep 30, 2025
Peapod Lane Capital LLC
561.87K
0.82%
+6.20K
+1.12%
Sep 30, 2025
Cantor Fitzgerald, L.P
547.17K
0.8%
-1.96M
-78.14%
Sep 30, 2025
Renaissance Technologies LLC
537.10K
0.79%
+41.60K
+8.40%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
ProShares Ultra Nasdaq Biotechnology
0.01%
iShares Biotechnology ETF
0.01%
Invesco Nasdaq Biotechnology ETF
0.01%
iShares Micro-Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Russell 2000 Growth ETF
0%
Proshares Ultra Russell 2000
0%
ProShares UltraPro Russell2000
0%
iShares Neuroscience and Healthcare ETF
0%
iShares Russell 2000 Value ETF
0%
詳細を見る
ProShares Ultra Nasdaq Biotechnology
比率0.01%
iShares Biotechnology ETF
比率0.01%
Invesco Nasdaq Biotechnology ETF
比率0.01%
iShares Micro-Cap ETF
比率0.01%
Avantis US Small Cap Equity ETF
比率0%
iShares Russell 2000 Growth ETF
比率0%
Proshares Ultra Russell 2000
比率0%
ProShares UltraPro Russell2000
比率0%
iShares Neuroscience and Healthcare ETF
比率0%
iShares Russell 2000 Value ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
